Ubic Inc. (ADR) (NASDAQ:UBIC) Valuable Mission is recognized by 21st Century Television. explained to 21st Century Television that they have come to the United States because they believe that to be successful in Asia, they must first be successful in the U.S. Their mission to develop software specifically for Asian languages has captured the attention of the Vice President of Programming, JL Haber who says, “Given Asia’s role in the technology sector, UBIC’s mission has the potential to help improve software for Asian languages could benefit multinational corporations throughout the world.” Ubic Inc. (ADR) (NASDAQ:UBIC) stock opened today at $10.07 and is currently trading at $10.50. The stock showed a positive weekly performance of 47.29%.
The FDA has granted its “breakthrough therapy” designation for a gene therapy treatment in mid-stage development by San Diego’s Celladon (NASDAQ:CLDN), for patients with advanced heart failure. Celladon Corp (NASDAQ:CLDN) stock opened at $12.50, in current trading session and currently is at $12.99, by gaining 0.49%. The 52 week range of $7.45 – $17.16. Company’s market capitalization is 240.32 million.
Ontario Teachers’ Pension Plan is the front-runner to acquire Loral (NASDAQ:LORL) Space & Communications Inc.’s Telesat Holdings Inc. for about $7 billion including debt, people with knowledge of the matter said. Loral Space & Communications Ltd. (NASDAQ:LORL) stock is currently trading at $74.10. The EPS of the stock is 0.66. Company’s market capitalization is 1.59 billion.
Analysts at Summer Street began coverage on shares of Durata Therapeutics (NASDAQ:DRTX) in a research report issued to clients and investors on Wednesday, Stock Ratings Network.com reports. The firm set a “buy” rating on the stock. Durata Therapeutics Inc. (NASDAQ:DRTX) stock opened the session at $13.40, and now is at $13.27. The 52 week range of the Durata Therapeutics Inc. (NASDAQ:DRTX) stock remained $6.65 – $16.99 and the day range was $13.25 – $13.41.